Chronic post-embolic pulmonary hypertension: a new target for medical therapies?}, Source: Eur Respir Rev 2013; 22: 258-264 Year: 2013
Repurposing benzbromarone for pulmonary arterial hypertension: can channelling the past deliver the therapy of the future? Source: Eur Respir J, 53 (6) 1900583; 10.1183/13993003.00583-2019 Year: 2019
Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?}, Source: Eur Respir Rev 2013; 22: 217-226 Year: 2013
Different treatment modalities in chronic thromboembolic pulmonary hypertension: how to combine them? Source: International Congress 2017 – Open questions in pulmonary vascular diseases Year: 2017
Thrombo-embolic pulmonary hypertension: which treatment should we choose? /
Hypertension pulmonaire thrombo-embolique: quel traitement choisir ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018
The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally! Source: Eur Respir J, 53 (3) 1900038; 10.1183/13993003.00038-2019 Year: 2019
Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better? Source: Eur Respir J 2006 Oct 01;28(4):683-686 Year: 2006
Treatment of pulmonary hypertension due to COPD: can we really hope in better? Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005
Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready? Source: Eur Respir J 2014; 44: 1404-1407 Year: 2014
Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet? Source: Eur Respir Rev 2014; 23: 458-468 Year: 2014
Chronic thromboembolic pulmonary hypertension: do we need a new definition? Source: Eur Respir J 2014; 44: 1401-1403 Year: 2014
Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010
Pulmonary hypertension: what can we learn from studies? Source: International Congress 2015 – Practising personalised medicine: why, when, and how? Year: 2015
The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities) Source: International Congress 2014 – Comorbidities Year: 2014
Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009
Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
Image-based recommendations for the evaluation of pulmonary embolism and arterial hypertension: what? when? how? Source: Virtual Congress 2020 – Image-based guidelines and recommendations in respiratory diseases Year: 2020
Combination therapy for pulmonary arterial hypertension: still more questions than answers Source: Eur Respir J 2004; 24: 339-340 Year: 2004
Optimising pharmacotherapy in patients with pulmonary arterial hypertension and comorbidities, including lung diseases and heart failure: benefits without harm? Source: International Congress 2018 – Integrated care for patients with pulmonary vascular disease, lung diseases and heart failure Year: 2018